JP2023546759A5 - - Google Patents
Info
- Publication number
- JP2023546759A5 JP2023546759A5 JP2023549958A JP2023549958A JP2023546759A5 JP 2023546759 A5 JP2023546759 A5 JP 2023546759A5 JP 2023549958 A JP2023549958 A JP 2023549958A JP 2023549958 A JP2023549958 A JP 2023549958A JP 2023546759 A5 JP2023546759 A5 JP 2023546759A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- sequence described
- bifunctional
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063104850P | 2020-10-23 | 2020-10-23 | |
| US63/104,850 | 2020-10-23 | ||
| PCT/US2021/056282 WO2022087435A1 (en) | 2020-10-23 | 2021-10-22 | Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546759A JP2023546759A (ja) | 2023-11-07 |
| JP2023546759A5 true JP2023546759A5 (cg-RX-API-DMAC7.html) | 2024-10-29 |
Family
ID=81290113
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023549958A Pending JP2023546759A (ja) | 2020-10-23 | 2021-10-22 | 腫瘍壊死因子－アルファおよびトランスフォーミング増殖因子－ベータの二機能性アンタゴニストならびにその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391892A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4232063A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2023546759A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230112629A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116744959A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2021365528A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3196077A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2023004725A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022087435A1 (cg-RX-API-DMAC7.html) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE469176T1 (de) * | 2001-11-12 | 2010-06-15 | Merck Patent Gmbh | Modifizierter anti-tnf antikörper |
| NZ590667A (en) * | 2008-07-02 | 2013-01-25 | Emergent Product Dev Seattle | Tgf-b antagonist multi-target binding proteins |
| CA3253628A1 (en) * | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| CN103732623B (zh) * | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| TWI476001B (zh) * | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| HRP20181939T4 (hr) * | 2013-03-20 | 2022-05-13 | Genzyme Corporation | Postupci za liječenje osteogenesis imperfecta |
| US10633423B2 (en) * | 2014-06-13 | 2020-04-28 | Affibody Ab | IL-6-binding polypeptide complex |
| MX364040B (es) * | 2016-11-11 | 2019-04-11 | Cell Therapy And Tech S A De C V | Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash). |
| MX2020009272A (es) * | 2018-03-06 | 2021-01-08 | Univ Pennsylvania | Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos. |
| GB201903767D0 (en) * | 2019-03-19 | 2019-05-01 | Quadrucept Bio Ltd | Multimers, tetramers & octamers |
-
2021
- 2021-10-22 WO PCT/US2021/056282 patent/WO2022087435A1/en not_active Ceased
- 2021-10-22 KR KR1020237017317A patent/KR20230112629A/ko active Pending
- 2021-10-22 US US18/033,337 patent/US20230391892A1/en active Pending
- 2021-10-22 CA CA3196077A patent/CA3196077A1/en active Pending
- 2021-10-22 JP JP2023549958A patent/JP2023546759A/ja active Pending
- 2021-10-22 AU AU2021365528A patent/AU2021365528A1/en active Pending
- 2021-10-22 EP EP21884002.3A patent/EP4232063A4/en active Pending
- 2021-10-22 CN CN202180086722.1A patent/CN116744959A/zh active Pending
- 2021-10-22 MX MX2023004725A patent/MX2023004725A/es unknown